Pink SheetA European Medicines Agency safety probe has found that the benefits of the weight management drug Mysimba continue to outweigh its risks, although Currax Pharmaceuticals will need to provide more dat
Pink SheetThe European Medicines Agency wants to know how many patients worldwide have used Currax Pharmaceuticals ’ weight management drug, Mysimba (naltrexone/bupropion), as part of a safety review it has st
ScripNovo Nordisk A/S 's high-growth obesity drugs – Wegovy (semaglutide) and Saxenda (liraglutide) – do not meet commonly used US cost effectiveness benchmarks at current prices, according to draft eviden
Medtech InsightDeals In September BI, Inflammasome Ally In $160m Retinal Diseases Collaboration Boehringer Ingelheim International GmbH and Inflammasome Therapeutics Inc. agreed to co-develop up to three candida